Heritage Wealth Advisors Sells 38 Shares of Eli Lilly and Company (NYSE:LLY)

by · The Cerbat Gem

Heritage Wealth Advisors cut its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 3.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 1,090 shares of the company’s stock after selling 38 shares during the period. Heritage Wealth Advisors’ holdings in Eli Lilly and Company were worth $900,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Hurlow Wealth Management Group Inc. grew its holdings in shares of Eli Lilly and Company by 0.7% during the first quarter. Hurlow Wealth Management Group Inc. now owns 6,138 shares of the company’s stock worth $5,069,000 after purchasing an additional 40 shares during the last quarter. Commerce Bank boosted its position in Eli Lilly and Company by 7.4% during the 1st quarter. Commerce Bank now owns 176,376 shares of the company’s stock worth $145,671,000 after buying an additional 12,162 shares during the period. MONECO Advisors LLC grew its holdings in Eli Lilly and Company by 0.6% during the 1st quarter. MONECO Advisors LLC now owns 4,123 shares of the company’s stock worth $3,405,000 after acquiring an additional 23 shares during the last quarter. Moors & Cabot Inc. increased its position in Eli Lilly and Company by 7.8% in the 1st quarter. Moors & Cabot Inc. now owns 22,036 shares of the company’s stock valued at $18,199,000 after acquiring an additional 1,598 shares during the period. Finally, Nicolet Advisory Services LLC raised its stake in shares of Eli Lilly and Company by 16.0% during the first quarter. Nicolet Advisory Services LLC now owns 3,814 shares of the company’s stock valued at $3,150,000 after acquiring an additional 527 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target on the stock. HSBC cut Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their price target for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Guggenheim increased their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the company a “buy” rating in a research report on Friday, July 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.56.

Read Our Latest Analysis on LLY

Eli Lilly and Company Stock Performance

Shares of LLY opened at $739.62 on Friday. The stock has a 50-day moving average of $774.56 and a 200-day moving average of $799.73. The company has a market cap of $700.97 billion, a PE ratio of 60.18, a P/E/G ratio of 1.08 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.58 earnings per share. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).